Protagonist Therapeutics (PTGX) EBITDA (2015 - 2026)
Protagonist Therapeutics (PTGX) reported EBITDA of -$3.6 million for Q1 2026, up 81.11% on a YoY basis from -$2.0 million in Q1 2025, and up 92.76% sequentially from -$50.4 million in Q4 2025.
Protagonist Therapeutics (PTGX) EBITDA (2015 - 2026) Analysis & Trends
Protagonist Therapeutics (PTGX) has 12 years of EBITDA data on file, last reported at -$3.6 million in Q1 2026.
- For the quarter ending Q1 2026, EBITDA rose 81.11% year-over-year to -$3.6 million; the trailing twelve-month figure through Mar 2026 stood at -$142.5 million (down 623.31% YoY), and the FY2025 full-year result was -$158.1 million, down 162.54% from the prior year.
- EBITDA advanced to -$3.6 million in Q1 2026, from -$50.4 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of $206.3 million in Q1 2024 to a low of -$50.4 million in Q4 2025.
- A 5-year average of -$7.9 million and a median of -$36.5 million in 2022 frame the typical range for EBITDA.
- Across the five-year window, EBITDA soared 672.75% in 2024 and slumped 139.72% in 2025, its largest moves.
- Tracing PTGX's EBITDA over 5 years: stood at -$36.5 million in 2022, then surged by 163.12% to $23.0 million in 2023, then surged by 450.05% to $126.8 million in 2024, then tumbled by 139.72% to -$50.4 million in 2025, then jumped by 92.76% to -$3.6 million in 2026.
- Business Quant data shows PTGX's EBITDA at -$3.6 million in Q1 2026, -$50.4 million in Q4 2025, and -$46.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 394.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -445.22 Mn |
| 10 | Protagonist Therapeutics | 8.88 Bn | 8.88 Bn | - | -3.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.65 Mn |
| Dec 31, 2025 | -50.36 Mn |
| Sep 30, 2025 | -46.42 Mn |
| Jun 30, 2025 | -42.04 Mn |
| Mar 31, 2025 | -19.31 Mn |
| Dec 31, 2024 | 126.78 Mn |
| Sep 30, 2024 | -41.45 Mn |
| Jun 30, 2024 | -38.79 Mn |
| Mar 31, 2024 | 206.31 Mn |
| Dec 31, 2023 | 23.05 Mn |
| Sep 30, 2023 | -38.33 Mn |
| Jun 30, 2023 | -42.35 Mn |
| Mar 31, 2023 | -36.02 Mn |
| Dec 31, 2022 | -36.52 Mn |
| Sep 30, 2022 | -32.30 Mn |
| Jun 30, 2022 | -41.44 Mn |
| Mar 31, 2022 | -21.11 Mn |
| Dec 31, 2021 | -37.02 Mn |
| Sep 30, 2021 | -33.93 Mn |
| Jun 30, 2021 | -30.88 Mn |